Abstract Search

ea0086oc3.3 | Reproductive and Neuroendocrinology | SFEBES2022

Long-term efficacy and safety of oral, once-daily paltusotine treatment in acromegaly: Two-year interim results from the ACROBAT Advance study

Randeva Harpal , Gadelha Monica , Gordon Murray , Doknic Mirjana , Mezősi Emese , Toth Miklos , Boguszewski Cesar , Ferrara-Cook Christine , Casagrande Alessandra , Krasner Alan

Paltusotine is an investigational oral, once-daily, non-peptide, SST2 agonist in development for the treatment of acromegaly and neuroendocrine tumors. Interim analysis results from subjects with acromegaly treated with paltusotine for up to 2 years in ACROBAT Advance (NCT04261712), an ongoing, open-label extension study are reported here. Prior to Advance, subjects previously completed one of two Phase 2 parent studies, Evolve (NCT03792555, with normal IGF-1 using injected lo...

0 shares

ea0077p80 | Neuroendocrinology and Pituitary | SFEBES2021

ACROBAT Advance: progress report on a study of long-term safety and efficacy of paltusotine for the treatment of acromegaly

Randeva Harpal , R . Gadelha Monica , Gordon Murray B. , Mezosi Emese , Doknic Mirjana , Toth Miklos , Boguszewski Cesar , Jochelson Theresa , Nichols Melissa , Luo Rosa , Madan Ajay , Ferrara-Cook Christine , Krasner Alan , Casagrande Alessandra , Scott Struthers R.

Paltusotine is a once-daily, oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist, which is in clinical development for the treatment of acromegaly. Maintenance of insulin-like growth factor 1 (IGF-1) control and toleration was demonstrated in phase 2 studies evaluating paltusotine in biochemically controlled (IGF-1 ≤1xULN) [ACROBAT Evolve (NCT03792555)] and uncontrolled (1> IGF-1 ≤2.5xULN) [ACROBAT Edge (NCT03789656)] patients with acromegaly ...

1 shares

ea0081oc4.6 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

ACROBAT advance: once daily, oral paltusotine treatment maintained long-term igf-1 at levels previously achieved with injectable long-acting somatostatin receptor ligands (LA-SRLs)

Gadelha Monica R , Randeva Harpal , Gordon Murray B , Mezosi Emese , Doknic Mirjana , Toth Miklos , Boguszewski Cesar L , Nichols Melissa , Jochelson Theresa , Henley Scott , Patel Meenal , Mendez Debbie Koh , Ferrara-Cook Christine , Krasner Alan , Casagrande Alessandra , Struthers R Scott

Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...

0 shares

Endocrine Abstracts

Long-term efficacy and safety of oral, once-daily paltusotine treatment in acromegaly: Two-year interim results from the ACROBAT Advance study

ACROBAT Advance: progress report on a study of long-term safety and efficacy of paltusotine for the treatment of acromegaly

ACROBAT advance: once daily, oral paltusotine treatment maintained long-term igf-1 at levels previously achieved with injectable long-acting somatostatin receptor ligands (LA-SRLs)

BiosciAbstracts